Myeloperoxidase-C2 (FITC) and CD3 (Pe) Antibody – Mouse

Myeloperoxidase (MPO) is a glycoprotein present in the azurophil (primary) granules of myeloid cells, which appears in the myeloblast stage of myeloid cell differentiation. MPO is he most common functional protein of myeloid cells and is involved in the inflammatory response. It helps to kill microbes by breaking down peroxide in the presence of halide ions, contributing to the bactericidal function of granulocytes. The primary translation product of MPO undergoes glycosylation with production of the 89 kDa heme-free apopro-MPO form followed by incorporation of heme and conversion into the enzymatically active pro-MPO form. Subsequently, pro-MPO becomes targeted to azurophil granules where final processing occurs to produce mature dimeric MPO consisting of the 59-64 kDa MPO a-chain and the 14 kDa MPO b-chain.

Precursor T-cells are surface CD3 negative but positive for cytoplasmatic CD3. All mature T cells are both cytoplasmic and surface CD3 positive. The combined staining for MPO and CD3 allows the distinction of cells derived form the myeloid lineage that are generally MPO positive, from immature and mature T lymphocytes during normal and malignant hematopoiesis.

The MPO-C2/CD3 COMBI-IC reagent permits the identification and enumeration of normal and malignant human blood and bone marrow cells using flow cytometry. Results must be put within the context of other tests as well as the clinical history of the patient by a certified professional before final interpretation. Analysis performed with this antibody should be paralleled by positive and negative controls.

Andersson, E., Hellman, L., Gullberg, U. & Olsson, I. (1998) J Biol Chem 273, 4747-53.
Beverley, P. C., Linch, D. & Callard, R. E. (1981) Haematol Blood Transfus 26, 309-13
Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7.
Campana, D., Thompson, J. S., Amlot, P., Brown, S. & Janossy, G. (1987) J Immunol 138, 648-55.
Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21.
Cowland, J. B. & Borregaard, N. (1999) J Leukoc Biol 66, 989-95.
Cramer, E., Pryzwansky, K. B., Villeval, J. L., Testa, U. & Breton-Gorius, J. (1985) Blood 65, 423-32
Groeneveld, K., te Marvelde, J. G., van den Beemd, M. W., Hooijkaas, H. & van Dongen, J. J. (1996) Leukemia 10, 1383-9.
Imamura, N. (1998) Am J Hematol 58, 241-3.
Janossy, G., Coustan-Smith, E. & Campana, D. (1989) Leukemia 3, 170-81.
Knapp, W., Majdic, O. & Strobl, H. (1993) Recent Results Cancer Res 131, 31-40.
Koeffler, H. P., Ranyard, J. & Pertcheck, M. (1985) Blood 65, 484-91.
Konikova, E., Glasova, M., Kusenda, J. & Babusikova, O. (1998) Neoplasma 45, 282-91.
Murao, S., Stevens, F. J., Ito, A. & Huberman, E. (1988) Proc Natl Acad Sci U S A 85, 1232-6.
Nakase, K., Sartor, M. & Bradstock (1998) Cytometry 34, 198-202.
Nauseef, W. M. (1990) Hematol Pathol 4, 165-78.
Nauseef, W. M., Olsson, I. & Arnljots, K. (1988) Eur J Haematol 40, 97-110.
Paietta, E. (2003) Best Pract Res Clin Haematol 16, 671-83.
Rani, S., De Oliveira, M. S. & Catovsky, D. (1988) Hematol Pathol 2, 73-8.
Srivastava, C. H., Rado, T. A., Bauerle, D. & Broxmeyer, H. E. (1991) J Immunol 146, 1014-9
Strobl, H. & Knapp, W. (2004) J Biol Regul Homeost Agents 18, 335-9.
Strobl, H., Takimoto, M., Majdic, O., Fritsch, G., Scheinecker, C., Hocker, P. & Knapp, W. (1993) Blood 82, 2069-78.
Tsuruta, T., Tani, K., Hoshika, A. & Asano, S. (1999) Leuk Lymphoma 32, 257-67.
Vainchenker, W., Villeval, J. L., Tabilio, A., Matamis, H., Karianakis, G., Guichard, J., Henri, A., Vernant, J. P., Rochant, H. & Breton-Gorius, J. (1988) Leukemia 2, 274-81.
van der Schoot, C. E., Daams, G. M., Pinkster, J., Vet, R. & von dem Borne, A. E. (1990) Br J Haematol 74, 173-8.
Vainchenker, W., Villeval, J. L., Tabilio, A., Matamis, H., Karianakis, G., Guichard, J., Henri, A., Vernant, J. P., Rochant, H. & Breton-Gorius, J. (1988) Leukemia 2, 274-81.
van der Schoot, C. E., Daams, G. M., Pinkster, J., Vet, R. & von dem Borne, A. E. (1990) Br J Haematol 74, 173-8.
van der Schoot, C. E., von dem Borne, A. E. & Tetteroo, P. A. (1987) Acta Haematol 78 Suppl 1, 32-40.

Small volumes of anti-Myeloperoxidase-C2 (FITC) and CD3 (PE) antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS570355 is an antibody targeting Myeloperoxidase-C2 (FITC) and CD3 (PE). Also known as COMBI IC Reagent: Mouse anti Myeloperoxidase-C2 (FITC) and Mouse anti CD3 (PE). Reactive in Human. Host: Mouse.